8-K 1 a4659894.txt ZYMOGENETICS, INC. 8-K -------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2004 Date of Report (Date of earliest event reported) ------------ ZYMOGENETICS, INC. (Exact name of registrant as specified in its charter) Washington 0-33489 91-1144498 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification Number) 1201 Eastlake Avenue East Seattle, Washington 98102-3702 (Address of principal executive offices) (Zip Code) 206-442-6600 (Registrant's telephone number, including area code) Item 5. Other Events On June 9, 2004, ZymoGenetics, Inc. issued a press release announcing the receipt of a notice from Novo Nordisk exercising its extension right under an existing option and licensing agreement which gives them the right to exclusively license a limited number of proteins outside North America. Under the terms of this agreement, Novo Nordisk will extend the option agreement for two years and will pay ZymoGenetics $7.5 million each year. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits (c) Exhibits. 99.1 Press Release issued June 9, 2004 by ZymoGenetics, Inc. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZYMOGENETICS, INC. Date: June 9, 2004 By: /s/ JAMES A. JOHNSON -------------------------------- Name: James A. Johnson Title: Senior Vice President and Chief Financial Officer EXHIBIT INDEX Exhibit Document Description Number ------- -------------------- 99.1 Press release issued June 9, 2004 by ZymoGenetics, Inc.